Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study

Background/Aims Atezolizumab plus bevacizumab (ATE+BEV) therapy has become the recommended first-line therapy for patients with unresectable hepatocellular carcinoma (HCC) because of favorable treatment responses. However, there is a lack of data on sequential regimens after ATE+BEV treatment failur...

Full description

Bibliographic Details

Published in:	Clinical and Molecular Hepatology
Main Authors:	Young Eun Chon, Dong Yun Kim, Mi Na Kim, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Yeonjung Ha, Joo Ho Lee, Kwan Sik Lee, Beodeul Kang, Jung Sun Kim, Hong Jae Chon, Do Young Kim
Format:	Article
Language:	English
Published:	Korean Association for the Study of the Liver 2024-07-01
Subjects:	atezolizumab bevacizumab hepatocellular carcinoma lenvatinib sorafenib
Online Access:	http://e-cmh.org/upload/pdf/cmh-2023-0553.pdf